Literature DB >> 12597857

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

Ronit Sharon1, Ifat Bar-Joseph, Matthew P Frosch, Dominic M Walsh, James A Hamilton, Dennis J Selkoe.   

Abstract

Accumulation of misfolded proteins as insoluble aggregates occurs in several neurodegenerative diseases. In Parkinson's disease (PD) and dementia with Lewy bodies (DLB), alpha-synuclein (alpha S) accumulates in insoluble inclusions. To identify soluble alpha S oligomers that precede insoluble aggregates, we probed the cytosols of mesencephalic neuronal (MES) cells, normal and alpha S-transgenic mouse brains, and normal, PD, and DLB human brains. All contained highly soluble oligomers of alpha S whose detection was enhanced by delipidation. Exposure of living MES neurons to polyunsaturated fatty acids (PUFAs) increased alpha S oligomer levels, whereas saturated FAs decreased them. PUFAs directly promoted oligomerization of recombinant alphaS. Transgenic mice accumulated soluble oligomers with age. PD and DLB brains had elevated amounts of the soluble, lipid-dependent oligomers. We conclude that alpha S interacts with PUFAs in vivo to promote the formation of highly soluble oligomers that precede the insoluble alpha S aggregates associated with neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12597857     DOI: 10.1016/s0896-6273(03)00024-2

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  196 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

Review 2.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

3.  Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption.

Authors:  Emmalee M Jones; Manish Dubey; Phillip J Camp; Briana C Vernon; Jacek Biernat; Eckhard Mandelkow; Jaroslaw Majewski; Eva Y Chi
Journal:  Biochemistry       Date:  2012-03-14       Impact factor: 3.162

4.  Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling.

Authors:  Christine C Jao; Ani Der-Sarkissian; Jeannie Chen; Ralf Langen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-20       Impact factor: 11.205

5.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

Review 6.  Folding and misfolding of alpha-synuclein on membranes.

Authors:  Igor Dikiy; David Eliezer
Journal:  Biochim Biophys Acta       Date:  2011-09-16

Review 7.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

8.  Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein.

Authors:  Jun Liu; Min Shi; Zhen Hong; JianPeng Zhang; Joshua Bradner; Thomas Quinn; Richard P Beyer; Patrick L Mcgeer; ShengDi Chen; Jing Zhang
Journal:  Proteomics       Date:  2010-06       Impact factor: 3.984

9.  Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress.

Authors:  Michael Riedel; Olaf Goldbaum; Michael Wille; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2010-08-20       Impact factor: 3.444

10.  Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes.

Authors:  Katharina Pukass; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2013-11-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.